• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.

作者信息

Martínez Feito Ana, Plasencia-Rodríguez Chamaida, Navarro-Compán Victoria, Hernández-Breijo Borja, Nozal Pilar, Ángeles González María, Nuño Laura, Monjo Irene, Pascual-Salcedo Dora, Balsa Alejandro

机构信息

Immuno-Rheumatology group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain; Immunology Unit, La Paz University Hospital, Madrid, Spain.

Immuno-Rheumatology group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain; Rheumatology Department, La Paz University Hospital, Madrid, Spain.

出版信息

Semin Arthritis Rheum. 2020 Feb;50(1):E1-E2. doi: 10.1016/j.semarthrit.2019.06.021. Epub 2019 Jun 28.

DOI:10.1016/j.semarthrit.2019.06.021
PMID:31375255
Abstract
摘要

相似文献

1
Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.类风湿关节炎患者在先前使用英夫利昔单抗或阿达木单抗继发失败后改用利妥昔单抗后抗药物抗体水平降低。
Semin Arthritis Rheum. 2020 Feb;50(1):E1-E2. doi: 10.1016/j.semarthrit.2019.06.021. Epub 2019 Jun 28.
2
Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.血清抗肿瘤坏死因子（TNF）药物谷浓度及抗药物抗体（ADAb）对类风湿关节炎和轴向脊柱关节炎换药后抗TNF短期疗效的影响。
Joint Bone Spine. 2016 Oct;83(5):595-7. doi: 10.1016/j.jbspin.2015.07.015. Epub 2016 Apr 8.
3
Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.阿根廷真实世界中阿达木单抗、依那西普和英夫利昔单抗治疗类风湿关节炎患者的抗药物抗体发生率。
J Clin Rheumatol. 2018 Jun;24(4):177-182. doi: 10.1097/RHU.0000000000000612.
4
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.类风湿关节炎中阿达木单抗和英夫利昔单抗抗药物抗体的发生率和危险因素：一项欧洲回顾性多队列分析。
Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.
5
Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.抗核抗体的存在是类风湿关节炎患者在接受英夫利昔单抗或阿达木单抗治疗时出现抗药物抗体的一个风险因素。
PLoS One. 2020 Dec 14;15(12):e0243729. doi: 10.1371/journal.pone.0243729. eCollection 2020.
6
Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.借助治疗药物监测优化类风湿关节炎的生物治疗
Dan Med J. 2016 Nov;63(11).
7
Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.血清 IL-33 水平与自身抗体相关，但与类风湿关节炎生物制剂的临床反应无关。
Arthritis Res Ther. 2018 Jun 8;20(1):122. doi: 10.1186/s13075-018-1628-6.
8
An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.对阿达木单抗或依那西普在炎性关节病中继发临床失败所涉及机制的研究。
J Clin Rheumatol. 2015 Apr;21(3):115-9. doi: 10.1097/RHU.0000000000000229.
9
Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.开发一种基于酶联免疫吸附测定的竞争性结合分析法，用于分析接受阿达木单抗或英夫利昔单抗治疗患者的药物浓度和抗药物抗体水平。
Ther Drug Monit. 2016 Feb;38(1):32-41. doi: 10.1097/FTD.0000000000000229.
10
The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.抗药抗体对接受阿达木单抗、依那西普或英夫利昔单抗治疗的类风湿关节炎患者药物浓度及临床结局的影响：一项跨国、真实世界临床实践、非干预性研究的结果
PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017.